6WHO/UNICEF/ICCIDD. Assessment of iodine deficiency disorders and monitoring their elimination. A guide forpmgmmme managers [M]. 3rd ed. Switzerland: WHO press, 2007:32-34.
7Roh JK, Kang DW, Lee SH, et al. Significance of acute multiple brain irffarction on diffusion-weighted imaging[ J]. Stroke, 2000, 31 (3) : 688-694.
8Stroke-1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebro- vascular Disorders[J]. Stroke,1989, 20(10) :1407-1431.
9Rifai N, Ma J, Sacks FM, et al. Apolipoprotein (a) size and lipo- protein (a) concerntration and future risk angine pectoris with evi- dence of severe coronary atheroselerosis in men: the physicians, health study [J]. Clin Chem, 2004,50 : 1364.
10Elkind MS, Tai W, Coates K, et al. High-sensitivity C-reactlve protein, lipoprotein-associated phosphoIipase A2, and outcome after ischemic stroke[ J ]. Arch Int Med, 2006,166:2073.
5Ramos-Estebanez C, Moral-Area I, Gonzalez-Mandly A, et al. Vascular cognitive impairment in small vessel disease: clin- ical and neuropsychologtcal features of lacunar state and Binswanger's disease[J]. Age Ageing, 2011,40(2):175-180.
6Djuric D, Jakovljevie V, Rasise M A, et al. Homocysteine fo- lie acid and coronary artery disease: possible impact on prog- nosis and therapy[J]. Indian J Chest Dis Allied Sei, 2008,50 (1):39-48.
7Tian L, Long S Y, Li C W, et al. High-density lipoprotein subclass and particle size in coronary heart disease patients with or without diabetes[J]. Lipids Health Dis, 2012,11(1):54.
8Lo C M, Nordskog B K, Nauli A M, et al. Why does the gut choose apolipoprotein B48 but not B100 for chylomicron formation[J]. Am J Physiol Gastrointest Liver Physiol, 2008,294 (1):G344-352.
9Sun Y, Chien K L, Hsu H C, et al. Use of serum homocyste- ine to predict stroke,coronary heart disease and death in eth- nic Chinese. 12-year prospective cohort study[J]. Cire J, 2009, 73(8):1423-1430.
